How much do paid clinical trials in Waterbury pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Are clinical trials in Waterbury safe?

Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.

How do I join a study in Waterbury, CT?

Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.

What is the difference between a research center and a hospital study in Waterbury?

Dedicated research centers (listed on this page with their Google ratings) run studies as their core business — often healthy-volunteer and vaccine studies with structured compensation. Hospital and university studies tend to focus on patients with specific conditions. Both types are registered and IRB-supervised.

How often do new paid studies open in Waterbury?

Constantly — trials open and close enrollment every week. This page is refreshed weekly from the NIH registry. Join the email alert to be notified when a new study opens within 30 miles of Waterbury.

Paid Clinical Trials Waterbury, CT — 1146 Studies Recruiting (Jul 2026)

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer N/A Observational 200 participants sought

Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut (0.8 mi) · Sponsor: Abramson Cancer Center at Penn Medicine

See eligibility & contact on ClinicalTrials.gov (NCT06551116)

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PIK3CA Mutation, HER2- Negative Breast Cancer Phase 3 Interventional 540 participants sought

Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut (18.2 mi) · Sponsor: Relay Therapeutics, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT06982521)

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

Heart Failure Phase 4 Interventional 20 participants sought

Yale University — New Haven, Connecticut (18.2 mi) · Sponsor: Yale University

See eligibility & contact on ClinicalTrials.gov (NCT07281014)

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Fibromyalgia Phase 3 Interventional 620 participants sought

Clinical Research Site — Cromwell, Connecticut (20.4 mi) · Sponsor: Axsome Therapeutics, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT07398417)

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

Healthy Volunteer Study, Healthy Adults Phase 1 Interventional 139 participants sought

Pfizer Clinical Research Unit - New Haven — New Haven, Connecticut (18.2 mi) · Sponsor: Pfizer

See eligibility & contact on ClinicalTrials.gov (NCT07660731)

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Ovarian Cancer Recurrent Phase 1, Phase 2 Interventional 460 participants sought

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019) — New Haven, Connecticut (18.2 mi) · Sponsor: Merck Sharp & Dohme LLC

See eligibility & contact on ClinicalTrials.gov (NCT06843447)

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Solid Tumor Cancer, Locally Advanced Phase 1, Phase 2 Interventional 480 participants sought

Avenzo Therapeutics Recruiting Site — New Haven, Connecticut (18.2 mi) · Sponsor: Avenzo Therapeutics, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT07038343)

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Solid Tumors (Phase 1) Phase 1 Interventional 180 participants sought

Yale University — New Haven, Connecticut (18.2 mi) · Sponsor: Adcendo ApS

See eligibility & contact on ClinicalTrials.gov (NCT07362888)

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

Uncontrolled Hypertension Phase 2 Interventional 280 participants sought

Retension Clinical Site — Waterbury, Connecticut (0.8 mi) · Sponsor: Retension Pharmaceuticals. Inc.

See eligibility & contact on ClinicalTrials.gov (NCT07142356)

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA) Phase 3 Interventional 400 participants sought

Chase Medical Research LLC — Waterbury, Connecticut (0.8 mi) · Sponsor: Novo Nordisk A/S

See eligibility & contact on ClinicalTrials.gov (NCT07481630)

Type 1 Diabetes Extension Study

Type 1 Diabetes Mellitus, T1DM N/A Observational 111 participants sought

Yale University — New Haven, Connecticut (18.2 mi) · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

See eligibility & contact on ClinicalTrials.gov (NCT02734277)

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma Phase 2 Interventional 188 participants sought

Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut (18.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04671667)

CLOZAPINE Response in Biotype-1

Schizophrenia, Schizoaffective Disorder Phase 4 Interventional 524 participants sought

Hartford Healthcare — Hartford, Connecticut (23.0 mi) · Sponsor: University of Texas Southwestern Medical Center

See eligibility & contact on ClinicalTrials.gov (NCT04580134)

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Amyloidosis, Amyloid Cardiomyopathy Phase 3 Interventional 587 participants sought

Yale University School of Medicine - Section of Cardiology — New Haven, Connecticut (18.2 mi) · Sponsor: Eidos Therapeutics, a BridgeBio company

See eligibility & contact on ClinicalTrials.gov (NCT06563895)

Comparison of Uncomplicated Candidemia Therapy Duration in Children

Invasive Candidiasis N/A Interventional 420 participants sought

Yale New Haven Children's Hospital — New Haven, Connecticut (18.2 mi) · Sponsor: Arkansas Children's Hospital Research Institute

See eligibility & contact on ClinicalTrials.gov (NCT05763251)

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Relapsed Refractory Multiple Myeloma Phase 3 Interventional 508 participants sought

Research Site — New Haven, Connecticut (18.2 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT07391657)

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

Coronary Artery Disease, Heart Failure Systolic N/A Interventional 754 participants sought

Yale University — New Haven, Connecticut (18.2 mi) · Sponsor: Sunnybrook Health Sciences Centre

See eligibility & contact on ClinicalTrials.gov (NCT05427370)

Longitudinal Neural Fingerprinting of Opioid-use Trajectories

Opioid Use Disorder N/A Interventional 10 participants sought

MRRC at The Anlyan Center — New Haven, Connecticut (18.2 mi) · Sponsor: Yale University

See eligibility & contact on ClinicalTrials.gov (NCT06207162)

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer Phase 4 Interventional 700 participants sought

Hartford Hospital — Hartford, Connecticut (23.0 mi) · Sponsor: Novartis Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT05803941)

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Phase 2 Interventional 630 participants sought

Research Site — New Haven, Connecticut (18.2 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT05061550)

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Polymyositis, Dermatomyositis Phase 3 Interventional 240 participants sought

Research Site — New Haven, Connecticut (18.2 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT06455449)

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis, Ulcerative Colitis Chronic Phase 2 Interventional 140 participants sought

Medical Research Center of Connecticut, LLC — Hamden, Connecticut (13.3 mi) · Sponsor: Eli Lilly and Company

See eligibility & contact on ClinicalTrials.gov (NCT06598943)

Utility of PCD Diagnostics to Improve Clinical Care

Primary Ciliary Dyskinesia N/A Observational 50 participants sought

Pulmonary Division — Hartford, Connecticut (23.0 mi) · Sponsor: Connecticut Children's Medical Center

See eligibility & contact on ClinicalTrials.gov (NCT05889013)

fMRI and Opioid Abstinence

Drug Use Disorder, Opioid Dependence N/A Observational 240 participants sought

The APT Foundation — New Haven, Connecticut (18.2 mi) · Sponsor: Yale University

See eligibility & contact on ClinicalTrials.gov (NCT06651333)

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Barrett Esophagus, Barretts Esophagus With Dysplasia N/A Interventional 2,298 participants sought

Connecticut Clinical Research Institute — Bristol, Connecticut (9.0 mi) · Sponsor: University of Colorado, Denver

See eligibility & contact on ClinicalTrials.gov (NCT05530343)

Paid Clinical Trials in Waterbury, CT

Studies recruiting near Waterbury right now

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Type 1 Diabetes Extension Study

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

CLOZAPINE Response in Biotype-1

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Comparison of Uncomplicated Candidemia Therapy Duration in Children

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

Longitudinal Neural Fingerprinting of Opioid-use Trajectories

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Utility of PCD Diagnostics to Improve Clinical Care

fMRI and Opioid Abstinence

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Top-rated research centers in Waterbury

Chase Medical Research, LLC

Cheshire Clinical Research Consultants

Chase Medical Research, LLC

CT Clinical Research

Medical Research Center of Connecticut

Yale-Griffin Prevention Research Center

Clinical Research Consulting LLC

Pfizer New Haven Clinical Research Unit

Research Center for Clinical Studies, Inc.

Clinical trials in Waterbury: what's recruiting

How to enroll in a paid study in Waterbury

Frequently asked questions

Paid clinical trials near Waterbury

More of CT

New paid studies open every week